Bromhexine
Identification
- Name
- Bromhexine
- Accession Number
- DB09019
- Description
Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 376.13
Monoisotopic: 373.999323944 - Chemical Formula
- C14H20Br2N2
- Synonyms
- 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
- Bromexina
- Bromhexina
- Bromhexine
- Bromhexinum
- N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
- External IDs
- NA 274
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
- Product Ingredients
Ingredient UNII CAS InChI Key Bromhexine hydrochloride YC2ZOM3Z8V 611-75-6 UCDKONUHZNTQPY-UHFFFAOYSA-N - International/Other Brands
- Amiorel (Boehringer Ingelheim) / Bisolmed (Boehringer Ingelheim) / Bisolvon (Boehringer Ingelheim) / Bisolvon Chesty (Boehringer Ingelheim) / Fluibron
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image BROMHEXINE ELIXIR Elixir 4 mg/5ml Oral บริษัท พาตาร์แลบ (2517) จำกัด จำกัด 2013-05-08 Not applicable Thailand BROMXINE Tablet 8 mg Oral บริษัท โรงงานเภสัชกรรมแอตแลนติค จำกัด 1987-06-15 Not applicable Thailand คอนเฮกซิน Syrup 4 mg/5ml Oral บริษัท คอนติเนนเติล-ฟาร์ม จำกัด จำกัด 1998-03-18 Not applicable Thailand ดูทรอส Tablet 8 mg Oral บริษัท ไทยนครพัฒนา จำกัด 1996-03-26 Not applicable Thailand ดูทรอส Syrup 4 mg/5ml Oral บริษัท ไทยนครพัฒนา จำกัด 1997-12-10 Not applicable Thailand บรอนมูคอน Tablet 8 mg Oral ห้างหุ้นส่วนจำกัด สุพงษ์เภสัช 1983-06-28 Not applicable Thailand บรอนเคลีย ชนิดเม็ด Tablet 8 mg Oral บริษัท โปลิฟาร์ม จำกัด จำกัด 1985-08-20 Not applicable Thailand บรอนเคส ชนิดน้ำเชื่อม Syrup 4 mg/5ml Oral บริษัท โรงงานผลิตเวชภัณฑ์ชินต้าเทรดดิ้ง (1971) จำกัด จำกัด 2000-06-06 Not applicable Thailand บรอมซิดอน อิลิกซ์เซอร์ Solution Oral บริษัท โรงงานเภสัชอุตสาหกรรม เจเอสพี (ประเทศไทย) จำกัด (มหาชน) 2020-03-17 Not applicable Thailand บรอมซิน ไซรัป Syrup 4 mg/5ml Oral บริษัท ยูเมด้า จำกัด 2000-12-18 Not applicable Thailand - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ROBITUSSIN ME Bromhexine (4 MG/5ML) + Guaifenesin (100 MG/5ML) Syrup Oral บริษัท แกล็กโซสมิทไคล์น คอนซูมเมอร์ เฮลธ์แคร์ (ประเทศไทย) จำกัด 2020-06-10 Not applicable Thailand คูป้า Bromhexine hydrochloride (4 mg) + Guaifenesin (100 mg) Tablet บริษัท เอ็ม แอนด์ เอ็ช แมนูแฟคเจอริ่ง จำกัด 1988-03-22 Not applicable Thailand ดูทรอส เอ็กซ์ Bromhexine hydrochloride (4 mg/5mL) + Potassium guaiacolsulfonate (200 mg/5mL) Syrup บริษัท ไทยนครพัฒนา จำกัด 2013-02-06 Not applicable Thailand ทอไกลโคโล่ Bromhexine hydrochloride (2 mg/5mL) + Potassium guaiacolsulfonate (200 mg/5mL) Syrup บริษัท สยามเภสัช จำกัด 1985-09-17 Not applicable Thailand ทอไกลโคโล่ ชนิดเม็ด Bromhexine hydrochloride (4 mg) + Guaifenesin (100 mg) Tablet บริษัท สยามเภสัช จำกัด 1987-04-21 Not applicable Thailand เอ็กซ์โทแรนท์ Bromhexine hydrochloride (4 mg) + Guaifenesin (100 mg) Tablet บริษัท เคนยากุ (ประเทศไทย) จำกัด 1985-06-15 Not applicable Thailand ไบโซลวอน เอ็กซ์ Bromhexine (4 MG/5ML) + Guaifenesin (100 MG/5ML) Syrup Oral บริษัท ซาโนฟี่-อเวนตีส (ประเทศไทย) จำกัด 2017-03-18 Not applicable Thailand
Categories
- ATC Codes
- R05CB02 — Bromhexine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylmethylamines
- Direct Parent
- Phenylmethylamines
- Alternative Parents
- Benzylamines / 2-bromoanilines / Cyclohexylamines / Bromobenzenes / Aralkylamines / Aryl bromides / Trialkylamines / Primary amines / Organopnictogen compounds / Organobromides show 1 more
- Substituents
- 2-bromoaniline / Amine / Aniline or substituted anilines / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Benzylamine / Bromobenzene / Cyclohexylamine show 11 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organobromine compound, tertiary amino compound, substituted aniline (CHEBI:77032)
Chemical Identifiers
- UNII
- Q1J152VB1P
- CAS number
- 3572-43-8
- InChI Key
- OJGDCBLYJGHCIH-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
- IUPAC Name
- 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline
- SMILES
- CN(CC1=CC(Br)=CC(Br)=C1N)C1CCCCC1
References
- Synthesis Reference
U.S. Patent 3,336,308.
- General References
- External Links
- KEGG Drug
- D07542
- PubChem Compound
- 2442
- PubChem Substance
- 310264976
- ChemSpider
- 2348
- BindingDB
- 50239965
- 1753
- ChEBI
- 77032
- ChEMBL
- CHEMBL253376
- ZINC
- ZINC000000608220
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Bromhexine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Coronavirus Disease 2019 (COVID‑19) / Increased Risk of SARS-CoV-2 Infection 1 4 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Recruiting Treatment Abnormal Mucus Secretions / Respiratory Tract Diseases 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID 19 1 1 Not Yet Recruiting Treatment Pharmacokinetics 1 0 Enrolling by Invitation Prevention Antimalarials / Antirheumatic Agents / Coronavirus Disease 2019 (COVID‑19) / Enzyme Inhibitors / Hydroxychloroquine 1 Not Available Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Novel Coronavirus Pneumonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule 8 MG Injection Intramuscular; Intravenous 2 MG/ML Injection, solution 4 MG/2ML Suppository Rectal 16 MG Suppository Rectal 8 MG Solution Oral 2 mg/ml Solution Oral 4 mg/5ml Solution Oral 8 MG/5ML Tablet Oral 8 mg/1 Solution Respiratory (inhalation) 0.2 g Tablet, soluble Oral 8 mg Syrup Oral 150 mg/5mL Tablet 150 mg Syrup Oral 7.5 mg Solution Oral 80 mg Syrup Oral 4 mg/5ml Tablet Oral 8 mg Syrup Oral 200 ml Tablet, sugar coated Oral 8 mg/1 Solution Oral Tablet Oral 12 MG Solution Oral 12 MG/ML Solution Oral 8 MG/ML Syrup Oral 0.16 g Syrup Oral 0.08 g Powder Not applicable 1000 g/1000g Syrup Oral 0.04 g Tablet Oral 4 MG Cream Oral; Vaginal 80 mg Syrup Oral 100 ml Syrup Oral 8 MG/5ML Syrup Oral 50 mg Elixir Oral 8 MG/5ML Solution Oral 0.8 mg/ml Tablet 8 mg Elixir Oral 4 mg/5ml Capsule, liquid filled Oral 8 mg Solution Oral 160 mg Syrup Oral Injection Intramuscular; Intravenous 4 mg/2ml Syrup Oral 80 mg Syrup Oral 40 mg Solution Oral 0.16 g Syrup Oral 160 mg Solution Oral 0.08 g Syrup Oral 150 mg Syrup Oral 2 mg/5ml Tablet, film coated Oral 8 MG Solution Oral 0.04 g Tablet, sugar coated Oral Capsule Capsule Solution Syrup Tablet Tablet, film coated Syrup Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 232-235 U.S. Patent 3,336,308. - Predicted Properties
Property Value Source Water Solubility 0.00362 mg/mL ALOGPS logP 4.08 ALOGPS logP 4.42 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 19.89 ChemAxon pKa (Strongest Basic) 9.32 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 29.26 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 85.56 m3·mol-1 ChemAxon Polarizability 32.98 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0095000000-2c4f15e31beb22fd1178 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0090000000-4d3be1605bfa79609959 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0090000000-428c05c13a2a9e326945 LC-MS/MS Spectrum - LC-ESI-QTOF , positive LC-MS/MS splash10-03di-0390000000-b0ece5d5d6f8b78af198
Drug created on June 24, 2014 16:22 / Updated on February 21, 2021 18:52